أثر مضاف
مراجع

↑  Government of Canada، Canadian Centre for Occupational Health and Safety (2019). "Synergism and related terms : OSH Answers". www.ccohs.ca. مؤرشف من الأصل في 2023-01-27. اطلع عليه بتاريخ 2022-03-26.
↑  Rowland, M., & Tozer, T. (2011). Clinical pharmacokinetics and pharmacodynamics [electronic resource] : Concepts and applications (4th ed.). Philadelphia: Wolters Kluwer Health/Lippincott William & Wilkins.
1 2 3 4  Cascorbi، Ingolf (2012). "Drug interactions--principles, examples and clinical consequences". Deutsches Ärzteblatt International. ج. 109 ع. 33–34: 546–555, quiz 556. DOI:10.3238/arztebl.2012.0546. ISSN:1866-0452. PMC:3444856. PMID:23152742.
↑  Greco، W. R.؛ Bravo، G.؛ Parsons، J. C. (1995). "The search for synergy: a critical review from a response surface perspective". Pharmacological Reviews. ج. 47 ع. 2: 331–385. ISSN:0031-6997. PMID:7568331. مؤرشف من الأصل في 2023-01-13.
↑  Maton، P. N.؛ Burton، M. E. (1999). "Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use". Drugs. ج. 57 ع. 6: 855–870. DOI:10.2165/00003495-199957060-00003. ISSN:0012-6667. PMID:10400401. مؤرشف من الأصل في 2023-01-25.
↑  Brohan, Janette; Goudra, Basavana G. (1 Oct 2017). "The Role of GABA Receptor Agonists in Anesthesia and Sedation". CNS Drugs (بالإنجليزية). 31 (10): 845–856. DOI:10.1007/s40263-017-0463-7. ISSN:1179-1934. PMID:29039138. Archived from the original on 2023-02-14.
↑  Sanna, E., Garau, F., & Harris, R. (1995). Novel properties of homomeric beta 1 gamma-aminobutyric acid type A receptors: Actions of the anesthetics propofol and pentobarbital. Molecular Pharmacology, 47(2), 213.
↑  Jones, M., Harrison, N., Pritchett, D., & Hales, T. (1995). Modulation of the GABAA receptor by propofol is independent of the gamma subunit. The Journal of Pharmacology and Experimental Therapeutics, 274(2), 962-968.
↑  Lam، Dennis W؛ Reynolds، James N (1998). "Modulatory and direct effects of propofol on recombinant GABAA receptors expressed in Xenopus oocytes: Influence of α- and γ2-subunits". Brain Research. ج. 784 ع. 1–2: 179–187. DOI:10.1016/s0006-8993(97)01334-6. ISSN:0006-8993. PMID:9518600. مؤرشف من الأصل في 2022-06-15.
↑  Garcia، Paul؛ Kolesky، Scott؛ Jenkins، Andrew (1 مارس 2010). "General Anesthetic Actions on GABAA Receptors". Current Neuropharmacology. ج. 8 ع. 1: 2–9. DOI:10.2174/157015910790909502. ISSN:1570-159X. PMC:2866459. PMID:20808541. مؤرشف من الأصل في 2022-12-11.
↑  Harris، R.؛ Lazar، O.؛ Johansen، J.؛ Sebel، P. (1 يونيو 2006). "Interaction of Propofol and Sevoflurane on Loss of Consciousness and Movement to Skin Incision during General Anesthesia". Anesthesiology. ج. 104 ع. 6: 1170–1175. DOI:10.1097/00000542-200606000-00011. ISSN:0003-3022. PMID:16732087. مؤرشف من الأصل في 2022-11-27.
↑  Novaes, Rômulo Dias; Sartini, Marcus Vinicius Pessoa; Rodrigues, João Paulo Ferreira; Gonçalves, Reggiani Vilela; Santos, Eliziária Cardoso; Souza, Raquel Lopes Martins; Caldas, Ivo Santana (2016). "Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease". Antimicrobial Agents and Chemotherapy (بالإنجليزية). 60 (6): 3355–3364. DOI:10.1128/AAC.00343-16. ISSN:0066-4804. PMC:4879395. PMID:27001816.
↑  Allam, Gamal (2009). "Immunomodulatory effects of curcumin treatment on murine schistosomiasis mansoni". Immunobiology (بالإنجليزية). 214 (8): 712–727. DOI:10.1016/j.imbio.2008.11.017. PMID:19249123. Archived from the original on 2022-06-30.
↑  Jagetia, Ganesh Chandra; Aggarwal, Bharat B. (25 Jan 2007). ""Spicing Up" of the Immune System by Curcumin". Journal of Clinical Immunology (بالإنجليزية). 27 (1): 19–35. DOI:10.1007/s10875-006-9066-7. ISSN:0271-9142. PMID:17211725. Archived from the original on 2023-03-20.
↑  Nandakumar, Dalavaikodihalli Nanjaiah; Nagaraj, Viswanathan Arun; Vathsala, Palakkod Govindan; Rangarajan, Pundi; Padmanaban, Govindarajan (2006). "Curcumin-Artemisinin Combination Therapy for Malaria". Antimicrobial Agents and Chemotherapy (بالإنجليزية). 50 (5): 1859–1860. DOI:10.1128/AAC.50.5.1859-1860.2006. ISSN:0066-4804. PMC:1472230. PMID:16641461.
↑  Dang، Jingyi؛ Fu، Jun؛ Zhang، Zhao؛ Liu، Dong؛ Cheng، Debin؛ Fan، Hongbin (2021). "Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis". Annals of Translational Medicine. ج. 9 ع. 24: 1764. DOI:10.21037/atm-21-6033. ISSN:2305-5839. PMC:8756232. PMID:35071458. مؤرشف من الأصل في 2022-03-16.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  Kellogg، G. E.؛ Scarsdale، J. N.؛ Fornari، F. A. (1998). "Identification and hydropathic characterization of structural features affecting sequence specificity for doxorubicin intercalation into DNA double-stranded polynucleotides". Nucleic Acids Research. ج. 26 ع. 20: 4721–4732. DOI:10.1093/nar/26.20.4721. ISSN:0305-1048. PMC:147880. PMID:9753742. مؤرشف من الأصل في 2022-05-31.
↑  Zewail-Foote، Maha؛ Li، Ven-Shun؛ Kohn، Harold؛ Bearss، David؛ Guzman، Mary؛ Hurley، Laurence H (2001). "The inefficiency of incisions of ecteinascidin 743–DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent". Chemistry & Biology. ج. 8 ع. 11: 1033–1049. DOI:10.1016/s1074-5521(01)00071-0. ISSN:1074-5521. PMID:11731295.
↑  Hemanta Baruah؛ Colin G. Barry؛ Ulrich Bierbach (2004). "Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation". Current Topics in Medicinal Chemistry. ج. 4 ع. 15: 1537–1549. DOI:10.2174/1568026043387313. ISSN:1568-0266. PMID:15579095. مؤرشف من الأصل في 2022-05-31.
↑  Chou، Ting-Chao (2006). "Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies". Pharmacological Reviews. ج. 58 ع. 3: 621–681. DOI:10.1124/pr.58.3.10. ISSN:0031-6997. PMID:16968952. مؤرشف من الأصل في 2023-03-20.
↑  Roell، Kyle R.؛ Reif، David M.؛ Motsinger-Reif، Alison A. (2017). "An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines". Frontiers in Pharmacology. ج. 8: 158. DOI:10.3389/fphar.2017.00158. ISSN:1663-9812. PMC:5397413. PMID:28473769.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  Government of Canada، Canadian Centre for Occupational Health and Safety (2022). "Synergism and related terms : OSH Answers". www.ccohs.ca. مؤرشف من الأصل في 2023-01-27. اطلع عليه بتاريخ 2022-03-16.
↑  Jia، Jia؛ Zhu، Feng؛ Ma، Xiaohua؛ Cao، Zhiwei W.؛ Li، Yixue X.؛ Chen، Yu Zong (2009). "Mechanisms of drug combinations: interaction and network perspectives". Nature Reviews Drug Discovery. ج. 8 ع. 2: 111–128. DOI:10.1038/nrd2683. ISSN:1474-1776. PMID:19180105. مؤرشف من الأصل في 2022-11-20.
↑  Johnson، Malcolm (2004). "Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease". Proceedings of the American Thoracic Society. ج. 1 ع. 3: 200–206. DOI:10.1513/pats.200402-010MS. ISSN:1546-3222. PMID:16113435. مؤرشف من الأصل في 2022-06-17.
↑  "Seretide Full Prescribing Information, Dosage & Side Effects | MIMS Hong Kong". www.mims.com. مؤرشف من الأصل في 2023-03-25. اطلع عليه بتاريخ 2022-04-18.
↑  Volpe، Massimo؛ Tocci، Giuliano (2012). "Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic". Vascular Health and Risk Management. ج. 8: 371–380. DOI:10.2147/VHRM.S28359. ISSN:1178-2048. PMC:3383291. PMID:22745561.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  Kostis، John B. (2010). "Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination". American Journal of Therapeutics. ج. 17 ع. 2: 188–196. DOI:10.1097/MJT.0b013e3181a2ba2d. ISSN:1536-3686. PMID:19433970. مؤرشف من الأصل في 2022-06-26.
↑  Simons، Leon A. (2002). "Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia". The American Journal of Cardiology. ج. 90 ع. 7: 737–740. DOI:10.1016/s0002-9149(02)02600-0. ISSN:0002-9149. PMID:12356387. مؤرشف من الأصل في 2022-06-04.
↑  Jia، Jia؛ Zhu، Feng؛ Ma، Xiaohua؛ Cao، Zhiwei W.؛ Li، Yixue X.؛ Chen، Yu Zong (2009). "Mechanisms of drug combinations: interaction and network perspectives". Nature Reviews Drug Discovery. ج. 8 ع. 2: 111–128. DOI:10.1038/nrd2683. ISSN:1474-1776. PMID:19180105. مؤرشف من الأصل في 2022-11-20.
↑  "Combination Cancer Therapy - Cancer". Merck Manuals Consumer Version (بالإنجليزية الأمريكية). Archived from the original on 2022-08-20. Retrieved 2022-03-16.
↑  Shenfield، G. M. (1982). "Fixed combination drug therapy". Drugs. ج. 23 ع. 6: 462–480. DOI:10.2165/00003495-198223060-00003. ISSN:0012-6667. PMID:7049658. مؤرشف من الأصل في 2022-06-04.
↑  Leon, Martin B.; Rosing, Douglas R.; Bonow, Robert O.; Epstein, Stephen E. (25 Jan 1985). "Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris". American Journal of Cardiology (بالإنجليزية). 55 (3): B69–B80. DOI:10.1016/0002-9149(85)90615-0. ISSN:0002-9149. PMID:2857518. Archived from the original on 2023-04-11.
↑  Hsiang, Kuo-Wei; Ng, Yee-Yung; Lu, Ching-Liang; Chen, Tseng-Shing; Lin, Hsiao-Yi; Luo, Jiing-Chyuan; Wu, Jia-Min; Lin, Han-Chieh; Chang, Full-Young (2010). "Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients: Steroid therapy and peptic ulcer disease". British Journal of Clinical Pharmacology (بالإنجليزية). 70 (5): 756–761. DOI:10.1111/j.1365-2125.2010.03752.x. PMC:2997316.
↑  Drina، Musa (1 يونيو 2017). "Peptic ulcer disease and non-steroidal anti-inflammatory drugs". Australian Prescriber. ج. 40 ع. 3: 91–93. DOI:10.18773/austprescr.2017.037. PMC:5478398. PMID:28798512. مؤرشف من الأصل في 2022-11-24.
بوابة صيدلة